Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry

WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS). The poster presents insights about the timing of NGS relative to first-line therapy in lung cancer.